LabGenius combines artificial intelligence, robotic automation and synthetic biology to evolve next-generation protein therapeutics.

LabGenius develops therapeutics of high value for diseases of unmet need. The company deploys machine intelligence to model the relationship between DNA sequence and protein function, while improving the predictive accuracy of these models through experimental lab data generated through its smart robotic platform.

• Industry

  • AI & Machine Learning
  • Biotechnology

• Milestones

  • Lux investment: 2019

• Founders

  • James Field

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • Our CEO @jejfield comments on the appointment of Dr Edwin Moses as Chairman of LabGenius. Read more here:… https://t.co/DarnJaQxu1@labgeni_us - 02:51 PM Apr 20th
  • Pleased to welcome Dr Edwin Moses as Chairman of LabGenius. Read more about his appointment here:… https://t.co/txA0GmwI9P@labgeni_us - 11:02 AM Apr 20th
  • Delighted to announce the appointment of Edwin Moses as Chairman of LabGenius ‒ to have a Chairman of Edwin’s calib… https://t.co/t4SdmFwQpW@labgeni_us - 09:36 AM Apr 20th